# Osteoporosis – Bone Ossification Enhancers

## Length of Authorizations

365 Days

## Prior Authorization Criteria

1.  Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:
    1.  Allergy to medications not requiring prior approval
    2.  Contraindication to or drug interaction with medications not requiring prior approval
    3.  History of unacceptable/toxic side effects to medications not requiring prior approval
2.  The requested medication may be approved if there has been a therapeutic failure to no less than a 90-day trial of at least one preferred medication within the same class of the requested medication

## Additional Criteria

### Critical Information

Patients should only be on ONE of the therapeutic classes (bisphosphonates, calcitonin-salmon).

### Abaloparatide (TYMLOS™)

Additional Criteria for Abaloparatide (TYMLOS™)

Abaloparatide is indicated in postmenopausal women with osteoporosis at high risk for fracture.

1.  Patient is female and postmenopausal
2.  Diagnosis of osteoporosis
3.  Trial of bisphosphonates for greater than 365 days
4.  Total lifetime therapy of parathyroid hormone analogs does not exceed 730 days (2 years)

## Formulary

Endocrine Agents: Osteoporosis – Bone Ossification Enhancers

### Preferred

| Preferred         |      |
| :---------------- | ---: |
| Alendronate Tab   |      |
| Calcitonin-Salmon |      |
| Forteo            |      |
| Ibandronate       |      |

### Non-Preferred

| Non-Preferred    |      |
| :--------------- | ---: |
| Alendronate Susp |      |
| Fosamax Plus D   |      |
| Risedronate      |      |
| Tymlos           |      |

## Links

[Criteria]https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=57)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=22)